Cutia Therapeutics (HKG:2487)

Hong Kong · Delayed Price · Currency is HKD

1.950

-0.050 (-2.50%)

Aug 27, 2026, 4:08 PM HKT

-80.10% (1Y)

Market Cap	726.74M -76.6%
Revenue (ttm)	374.07M +20.2%
Net Income	-378.57M
EPS	-1.14
Shares Out	363.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	130,000
Open	1.830
Previous Close	2.000
Day's Range	1.830 - 2.000
52-Week Range	1.830 - 12.000
Beta	0.47
Analysts	Buy
Price Target	11.43 (+486.15%)
Earnings Date	Aug 31, 2026

About Cutia Therapeutics

Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong. It focuses on the dermatology treatment and care therapeutic areas, including scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management medication. The company provides CU-40102, a topical finasteride spray for androgenetic alopecia treatment; and CU-10201, a to... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2019

Employees 304

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2487

Full Company Profile

Financial Performance

In 2025, Cutia Therapeutics's revenue was 336.15 million, an increase of 20.22% compared to the previous year's 279.62 million. Losses were -340.19 million, -21.58% less than in 2024.

Financial numbers in CNY Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 2487 stock is "Buy." The 12-month stock price target is $11.43, which is an increase of 486.15% from the latest price.

Price Target

$11.43

(486.15% upside)

Analyst Consensus: Buy

Stock Forecasts